12-Jun-2026
Globe Newswire (Fri, 12-Jun 8:51 AM ET)
TipRanks (Tue, 9-Jun 8:05 AM ET)
TipRanks (Tue, 9-Jun 6:40 AM ET)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Thu, 21-May 4:05 PM ET)
Market Chameleon (Wed, 20-May 5:08 AM ET)
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
PRNewswire (Tue, 19-May 4:05 PM ET)
TransMedics Reports First Quarter 2026 Financial Results
PRNewswire (Tue, 5-May 4:05 PM ET)
PRNewswire (Wed, 29-Apr 9:27 AM ET)
PRNewswire (Thu, 23-Apr 7:00 AM ET)
TransMedics Sets Date for Q1 2026 Results—Will Earnings Spark Fresh Momentum?
Market Chameleon (Wed, 22-Apr 3:34 AM ET)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Transmedics Group trades on the NASDAQ stock market under the symbol TMDX.
As of June 12, 2026, TMDX stock price declined to $72.91 with 641,016 million shares trading.
TMDX has a beta of 1.32, meaning it tends to be more sensitive to market movements. TMDX has a correlation of 0.05 to the broad based SPY ETF.
TMDX has a market cap of $2.52 billion. This is considered a Mid Cap stock.
Last quarter Transmedics Group reported $174 million in Revenue and $.30 earnings per share. This fell short of revenue expectation by $-449,560 and missed earnings estimates by -$.31.
In the last 3 years, TMDX traded as high as $177.37 and as low as $36.42.
The top ETF exchange traded funds that TMDX belongs to (by Net Assets): IJR, VTI, VB, IWM, VBK.
TMDX has underperformed the market in the last year with a return of -49.0%, while the SPY ETF gained +24.1%. In the last 3 month period, TMDX fell short of the market, returning -39.9%, while SPY returned +11.6%. However, in the most recent 2 weeks TMDX has outperformed the stock market by returning +8.5%, while SPY returned -1.9%.
TMDX support price is $70.86 and resistance is $76.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TMDX shares will trade within this expected range on the day.